Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1584-1591

  Celen, Sofie ^a   Koole, Michel ^a   De Angelis, Meri ^b   Sannen, Ivan ^a   Chitneni, Satish K ^a   Alcazar, Jesus ^b   Dedeurwaerdere, Stefanie ^c   Moechars, Dieder ^c   Schmidt, Mark ^c   Verbruggen, Alfons ^a   Langlois, Xavier ^c   Van Laere, Koen ^a   Andrés, José Ignacio ^b   Bormans, Guy ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b JOHNSON AND JOHNSON   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

18F; Brain imaging; PDE10A; PET

Indexed keywords

DRUG METABOLITE; FLUORINE 18; JNJ 41510417; JNJ 41510417 F 18; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE INHIBITOR; RADIOLIGAND; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; JNJ41510417; PDE10A PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN HOMOGENATE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG SCREENING; EX VIVO STUDY; GENE INACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING;

ANIMALS; BRAIN; DRUG EVALUATION, PRECLINICAL; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; QUINOLINES; RADIOPHARMACEUTICALS; RATS; TISSUE DISTRIBUTION;

EID: 79851490485     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.077040     Document Type: Article

References (27)

1. Kehler J, Ritzén A, Rodriguez Greve D. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Patents. 2007;17:147-158.
2. Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A: isolation and characterization of a rat PDE10A. Eur J Biochem. 1999;266:1118-1127. (Pubitemid 30010131)
3. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985:113-126. (Pubitemid 37088176)
4. Coskran TM, Morton DG, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A, PDE10A, in multiple mammalian species. J Histochem Cytochem. 2006;54:1205-1213. (Pubitemid 44623341)
5. Siuciak JA, Chapin DS, Harms JF, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006;51:386-396. (Pubitemid 44061894)
6. Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatumenriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuopharmacology. 2006;51:374-385. (Pubitemid 44061880)
7. Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/B16N congenic background. Neuropharmacology. 2008;54:417-427.
8. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs. 2007;8:54-59. (Pubitemid 46438266)
9. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov. 2006;5:660-670. (Pubitemid 44151604)
10. Halene TB, Siegel SJ. PDE10 inhibitors in psychiatry: future options for dementia, depression and schizophrenia? Drug Discov Today. 2007;12: 870-878.
11. Lee C-M, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006;27:310-316. (Pubitemid 43870125)
12. Cunningham VJ, Parker CA, Rabiner EA, Gee AD, Gunn RN. PET studies in drug development: methodological considerations. Drug Discov Today. 2005;2:311-315. (Pubitemid 43115466)
13. Passchier J, Gee A, Willemsen A, Vaalburg W, van Waarde A. Measuring drugrelated receptor occupancy with positron emission tomography. Methods. 2002;27:278-286.
14. Wong DF, Tauscher J, Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacol. 2009;34:187-203.
15. Tu Z, Xu J, Jones LA, Li S, Mach RH. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol. 2010;37:509-516.
16. 1H-pyrazol-3-yl)-phenoxymethyl]- quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009;52:5188-5196.
17. Walker MA. Discovery of PDE10A inhibitor, PF-2545920. Drug Discov Today. 2010;15:79.
18. Verhoest PR, Helal CJ, Hoover DJ, Humphrey JM, inventors; Pfizer Products, Inc., USA, assignee. Heteroaromatic quinoline compounds as phosphodiesterase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. World patent WO 2006072828 A2. July 13, 2006.
19. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376-389. (Pubitemid 37489828)
20. Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30:431-440.
21. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area directly from SMILES. Novartis Pharma AG, ChemInformatics, Basel, Switzerland. Available at: http://www.daylight.com/meetings/emug00/Ertl/ index.html. Accessed July 27, 2010.
22. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714-3717.
23. Casteels C, Vermaelen P, Nuyts J, et al. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med. 2006;47:1858-1866. (Pubitemid 47545009)
24. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008;325:681-690. (Pubitemid 351574819)
25. 18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995;22:283-296.
26. 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med. 2006;47:520-527.
27. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096-1112.